A comprehensive review of the scientific literature identified more than 100 distinct ways in which off episodes affect people with Parkinson’s disease, highlighting a multifaceted burden that extends beyond movement symptoms to include cognitive, emotional, and quality-of-life impacts. The research was presented by Merz Therapeutics, the company that…
News
Foresee Pharmaceuticals’ oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing several experimental treatments for Parkinson’s disease. The trial, funded by Cure Parkinson’s and conducted in collaboration with Haukeland University Hospital in Bergen, Norway, is evaluating multiple therapeutic candidates…
Fecal microbiota transplantation (FMT), a technique for replacing gut bacteria, may help with gastrointestinal symptoms of Parkinson’s disease, particularly constipation, according to a review study. While the technique was found to be generally safe and beneficial for gastrointestinal symptoms in Parkinson’s disease, “at this stage, there is no convincing…
People with Parkinson’s disease who switched to the approved oral therapy Crexont, an extended-release formulation of carbidopa and levodopa, from other levodopa-based treatments gained about three additional hours of daily good on time — when symptoms are well-controlled — while also experiencing less off time, or periods…
Levodopa, a standard treatment for Parkinson’s disease, can cause uncontrolled movements called dyskinesia — and this side effect may be driven by changes in a specific receptor component in certain brain cells, a new study shows. Scientists found that an experimental gene therapy…
Montara Therapeutics received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a Parkinson’s disease treatment designed to work primarily in the brain and minimize effects on the rest of the body. The new drug will target the mTOR biological pathway.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded Lysoway Therapeutics $3.4 million in funding to support the development of an investigational therapy targeting the TMEM175 protein. The grant is part of the foundation’s Parkinson’s Disease Therapeutics Pipeline Program, which aims to accelerate the development of potential…
More than 2,000 potential participants have been identified for screening in a Parkinson’s clinical trial, thanks to the Parkinson’s Foundation‘s PD Trial Navigator matching program. The Phase 2 trial (NCT06680830), known as NEULARK, is evaluating Neuron23‘s experimental therapy, NEU-411, in up to 150 people with early-stage,…
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced. The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in…
A University of Minnesota Medical School team has received a $6 million grant to design mouse models for the study of genetic variants linked to Parkinson’s disease. “These models could help us better understand how Parkinson’s disease works and support testing of potential therapies in early stages of research,”…
Recent Posts
- Small US trial of Parkinson’s cell therapy hits ‘important milestone’
- Coming to terms with hearing loss, regardless of the cause
- Trial of fast-tracked new Parkinson’s cell therapy hits ‘critical’ step
- Parkinson’s disease taught me to find joy in ordinary moments
- Study ties gut bacteria to dopamine, Parkinson’s motor control